Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.41 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4973149 | 0.85 | SPPL2A (0.69) | SPPL2AALDH1A1HTTHPGDTAS2R14 | |
| SCHEMBL4787816 | 0.85 | SPPL2A (0.69) | SPPL2AALDH1A1HTTHPGDTAS2R14 | |
| SCHEMBL4911178 | 0.84 | SPPL2A (0.66) | SPPL2AALDH1A1HTTHPGDTAS2R14 | |
| SCHEMBL6061183 | 0.79 | SPPL2A (0.59) | SPPL2AALDH1A1KEAP1PSEN1PSEN2 | |
| SCHEMBL464764 | 0.79 | SPPL2A (0.59) | SPPL2AALDH1A1KEAP1PSEN1PSEN2 | |
| SCHEMBL4911572 | 0.77 | ALDH1A1 (0.53) | SPPL2AALDH1A1HTTHPGDTAS2R14 | |
| SCHEMBL4906010 | 0.77 | ALDH1A1 (0.53) | SPPL2AALDH1A1HTTHPGDTAS2R14 | |
| SCHEMBL14216612 | 0.76 | SPPL2A (0.55) | SPPL2ALMNA | |
| SCHEMBL2582404 | 0.75 | ALDH1A1 (0.53) | SPPL2AALDH1A1HTTHPGDTAS2R14 | |
| SCHEMBL14189478 | 0.75 | SPPL2A (0.54) | SPPL2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176842-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE LLC (US) | 2008-07-24 | — | — | US | disclosed |
| EP-0804428-B1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | SEARLE LLC (US) | 2007-12-26 | — | — | EP | disclosed |
| US-7297793-B2 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE, LLC (US) | 2007-11-20 | — | — | US | disclosed |
| US-20070004646-A1 | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-01-04 | — | — | US | disclosed |
| US-7141594-B2 | inhibitors of HIV protease for treating AIDS | G. D. SEARLE & CO. (US) | 2006-11-28 | — | — | US | disclosed |
| US-20060264483-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-11-23 | — | — | US | disclosed |
| US-20060240410-A1 | Retroviral protease inhibitor combinations | G.D. SEARLE & CO. (US) | 2006-10-26 | — | — | US | disclosed |
| US-20060199822-A1 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-09-07 | — | — | US | disclosed |
| US-7098202-B2 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2006-08-29 | — | — | US | disclosed |
| US-20060189611-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-08-24 | — | — | US | disclosed |
| EP-1076062-A1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2001-02-14 | — | — | EP | disclosed |
| US-6172101-B1 | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS | G. D. SEARLE & CO. | 2001-01-09 | — | — | US | disclosed |
| US-6150556-A | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS(HIV) PROTEASE; PROPHYLAXIS AND THERAPY OF RETROVIRUS INFECTIONS | G. D. DEARLE & CO. (US) | 2000-11-21 | — | — | US | disclosed |
| EP-1052250-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2000-11-15 | — | — | EP | disclosed |
| US-6143747-A | ENZYME INHIBITORS | G. D. SEARLE & CO. (US) | 2000-11-07 | — | — | US | disclosed |
| US-6127556-A | Epoxide formation by continuous in-situ synthesis process | G. D. SEARLE & CO. (US) | 2000-10-03 | — | — | US | disclosed |
| US-6063795-A | ENZYME INHIBITORS | G.D. SEARLE & COMPANY (US) | 2000-05-16 | — | — | US | disclosed |
| US-5968970-A | TREATMENT OF HIV | G. D. SEARLE & COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| US-5965601-A | NOVEL COMPOUNDS FOR INHIBITING REPLICATION OF A RETROVIRUS; TREATING HIV | G. D. SEARLE & CO. (US) | 1999-10-12 | — | — | US | disclosed |
| WO-1996028463-A1 | AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176842-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | PRSS1, DNPEP, PREP | SPPL2A 636/4885ALDH1A1 2674/4885HTT 1097/4885 |
| US-20070004646-A1 | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, ANPEP | SPPL2A 282/4885ALDH1A1 3417/4885HTT 389/4885 |
| US-20060199822-A1 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | PRSS1, DNPEP, PREP | SPPL2A 636/4885ALDH1A1 2674/4885HTT 1097/4885 |
| US-20060264483-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, PRSS1 | SPPL2A 349/4885ALDH1A1 3190/4885HTT 365/4885 |
| US-20060189611-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, ANPEP | SPPL2A 268/4885ALDH1A1 3732/4885HTT 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.